Shl Telemedicine Ltd. (CH:SHLTN)
:SHLTN
Want to see CH:SHLTN full AI Analyst Report?
Top Page
Shl Telemedicine
(SHLTN)
Select Model
Select Model
Rating:44Neutral
Price Target:
CHF1.00
Action:N/ADate:04/08/26
The score is primarily held back by weak financial performance driven by continued losses and negative free cash flow, despite a moderately supported balance sheet. Technical indicators are broadly neutral and do not provide a strong offset, while valuation remains challenged due to negative earnings and no dividend support.
Positive Factors
Supported balance sheet
Declining total debt and higher equity in 2025 provide structural balance-sheet support, lowering refinancing risk and giving management time to execute a turnaround. A manageable debt-to-equity range helps preserve financial flexibility during multi-quarter recovery efforts.
Negative Factors
Persistent cash burn
Multi-year negative operating and free cash flow signal ongoing cash burn that undermines self-funding capacity. This structural cash shortfall increases reliance on external financing, raising dilution or credit risk and constraining long-term investment in growth initiatives.
Read all positive and negative factors
Positive Factors
Negative Factors
Supported balance sheet
Declining total debt and higher equity in 2025 provide structural balance-sheet support, lowering refinancing risk and giving management time to execute a turnaround. A manageable debt-to-equity range helps preserve financial flexibility during multi-quarter recovery efforts.
Read all positive factors
Shl Telemedicine (SHLTN) vs. iShares MSCI Switzerland ETF (EWL)
Market Cap
CHF38.91M
Dividend YieldN/A
Average Volume (3M)15.43K
Price to Earnings (P/E)―
Beta (1Y)0.74
Revenue Growth-2.63%
EPS Growth40.87%
CountryCH
Employees526
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)N/A
Shares Outstanding37,059,944
10 Day Avg. Volume8,507
30 Day Avg. Volume15,434
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.73
Price to Sales (P/S)0.52
P/FCF Ratio-9.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Shl Telemedicine Business Overview & Revenue Model
Company Description
SHL Telemedicine Ltd., together with its subsidiaries, develops and markets personal telemedicine solutions in Israel, Europe, and internationally. The company offers smartheart, a personal mobile 12 lead ECG device that enables the detection of h...
How the Company Makes Money
null...
Shl Telemedicine Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
60
Neutral
Cash Flow
32
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 61.49M | 56.78M | 57.08M | 59.00M | 49.58M |
| Gross Profit | 22.89M | 25.79M | 25.26M | 27.19M | 24.59M |
| EBITDA | 3.28M | -18.15M | 3.02M | 9.48M | 4.35M |
| Net Income | -16.11M | -28.09M | -7.06M | -76.00K | -14.11M |
Balance Sheet | |||||
| Total Assets | 84.56M | 80.76M | 113.05M | 110.78M | 129.59M |
| Cash, Cash Equivalents and Short-Term Investments | 25.26M | 17.52M | 26.25M | 18.70M | 32.06M |
| Total Debt | 13.08M | 16.12M | 19.86M | 26.74M | 32.50M |
| Total Liabilities | 40.82M | 41.51M | 36.59M | 51.49M | 68.83M |
| Stockholders Equity | 43.74M | 39.25M | 73.53M | 55.69M | 56.85M |
Cash Flow | |||||
| Free Cash Flow | -3.48M | -4.04M | -6.99M | -1.73M | -3.07M |
| Operating Cash Flow | -1.90M | -372.00K | -1.50M | -73.00K | 185.00K |
| Investing Cash Flow | 7.93M | 6.03M | -9.35M | -6.43M | -40.97M |
| Financing Cash Flow | 11.02M | -4.87M | 13.67M | -2.28M | 51.08M |
Shl Telemedicine Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
Shl Telemedicine Corporate Events
SHL Telemedicine Narrows Loss and Bolsters Balance Sheet as Turnaround Advances
Mar 31, 2026
SHL Telemedicine reported 2025 revenues of USD 59 million, broadly stable year-on-year, while lifting gross margin to 47% and cutting its net loss to USD 15.4 million as restructuring gains and sharply lower one-off charges took effect. Adjusted E...
SHL Telemedicine Moves to Deregister from SEC, Focuses on Swiss Listing
Feb 2, 2026
SHL Telemedicine has moved to voluntarily terminate its registration with the U.S. Securities and Exchange Commission by filing Form 15F, ending the SEC reporting obligations tied to its ordinary shares following the earlier delisting and terminat...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.